{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:32:28Z","timestamp":1767889948730,"version":"3.49.0"},"reference-count":168,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001755","name":"Mesothelioma Applied Research Foundation","doi-asserted-by":"publisher","award":["ID 483418"],"award-info":[{"award-number":["ID 483418"]}],"id":[{"id":"10.13039\/100001755","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Italian Ministry of Health","award":["Ricerca Corrente (M4\/7)"],"award-info":[{"award-number":["Ricerca Corrente (M4\/7)"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Malignant mesothelioma (MM) is a deadly tumor mainly caused by exposure to asbestos. Unfortunately, no current treatment is able to change significantly the natural history of the disease, which has a poor prognosis in the majority of patients. The non-receptor tyrosine kinase SRC and other SRC family kinase (SFK) members are frequently hyperactivated in many cancer types, including MM. Several works have indeed suggested that SFKs underlie MM cell proliferation, survival, motility, and invasion, overall affecting multiple oncogenic pathways. Consistently, SFK inhibitors effectively counteracted MM cancerous features at the preclinical level. Dasatinib, a multi-kinase inhibitor targeting SFKs, was also assessed in clinical trials either as second-line treatment for patients with unresectable MM or, more recently, as a neoadjuvant agent in patients with resectable MM. Here, we provide an overview of the molecular mechanisms implicating SFKs in MM progression and discuss possible strategies for a more successful clinical application of SFK inhibitors. Our aim is to stimulate discussion and further consideration of these agents in better designed preclinical and clinical studies to make the most of another class of powerful antitumoral drugs, which too often are lost in translation when applied to MM.<\/jats:p>","DOI":"10.3390\/cancers12071866","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T11:03:23Z","timestamp":1594724603000},"page":"1866","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Targeting SRC Family Kinases in Mesothelioma: Time to Upgrade"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8416-435X","authenticated-orcid":false,"given":"Paola","family":"Indovina","sequence":"first","affiliation":[{"name":"Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA"},{"name":"Institute for High Performance Computing and Networking, National Research Council of Italy (ICAR-CNR), I-80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-5844","authenticated-orcid":false,"given":"Iris Maria","family":"Forte","sequence":"additional","affiliation":[{"name":"Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, I-80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4740-6801","authenticated-orcid":false,"given":"Francesca","family":"Pentimalli","sequence":"additional","affiliation":[{"name":"Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, I-80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5959-016X","authenticated-orcid":false,"given":"Antonio","family":"Giordano","sequence":"additional","affiliation":[{"name":"Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA"},{"name":"Department of Medical Biotechnologies, University of Siena, I-53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Hiriart, E., Deepe, R., and Wessels, A. (2019). Mesothelium and Malignant Mesothelioma. J. Dev. Biol., 7.","DOI":"10.3390\/jdb7020007"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.critrevonc.2016.05.004","article-title":"The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations","volume":"104","author":"Novello","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Scherpereel, A., Opitz, I., Berghmans, T., Psallidas, I., Glatzer, M., Rigau, D., Astoul, P., B\u00f6l\u00fckbas, S., Boyd, J., and Coolen, J. (2020). ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur. Respir. J., 55.","DOI":"10.1183\/13993003.00953-2019"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/10937404.2016.1195322","article-title":"Environmental risk of mesothelioma in the United States: An emerging concern-epidemiological issues","volume":"19","author":"Baumann","year":"2016","journal-title":"J. Toxicol. Environ. Health. B Crit. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.21037\/atm.2017.04.29","article-title":"Mesothelioma: Recent highlights","volume":"5","author":"Carbone","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach","volume":"15","author":"Nicholson","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","article-title":"The 2015 world health organization classification of tumors of the pleura: Advances since the 2004 Classification","volume":"11","author":"Churg","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"The Lancet Respiratory Medicine (2019). Pleural mesothelioma: Tackling a deadly cancer. Lancet Respir. Med., 7, 99.","DOI":"10.1016\/S2213-2600(19)30004-9"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semcancer.2019.09.014","article-title":"Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies","volume":"61","author":"Hinz","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/1878-0261.12651","article-title":"Genetic alterations of malignant pleural mesothelioma: Association with tumor heterogeneity and overall survival","volume":"14","author":"Quetel","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Oehl, K., Vrugt, B., Opitz, I., and Meerang, M. (2018). Heterogeneity in malignant pleural mesothelioma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19061603"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jare.2014.11.012","article-title":"Mesothelioma treatment: Are we on target? A review","volume":"6","author":"Hiddinga","year":"2015","journal-title":"J. Adv. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jtho.2018.02.021","article-title":"Progress in the Management of Malignant Pleural Mesothelioma in 2017","volume":"13","author":"McCambridge","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1158\/0008-5472.CAN-18-4093","article-title":"Inactivation of Bap1 Cooperates with Losses of Nf2 and Cdkn2a to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models","volume":"79","author":"Kukuyan","year":"2019","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1111\/jcmm.15213","article-title":"PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach","volume":"24","author":"Barbarino","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Sato, T., and Sekido, Y. (2018). NF2\/merlin inactivation and potential therapeutic targets in mesothelioma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19040988"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/JTO.0000000000000493","article-title":"Hippo pathway gene mutations in malignant mesothelioma: Revealed by RNA and targeted exon sequencing","volume":"10","author":"Miyanaga","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1158\/1078-0432.CCR-11-2375","article-title":"New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment","volume":"18","author":"Ladanyi","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_23","unstructured":"Giordano, A., and Franco, R. (2019). Insert: Molecular markers f mesothelioma aiding in diagnostic challenge: The combined use of p16 and BAP1. Malignant Pleural Mesothelioma: A Guide for Clinicians, Academic Press Inc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e1167","DOI":"10.1038\/cddis.2014.136","article-title":"Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation","volume":"5","author":"Cioce","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nrc1366","article-title":"A renaissance for SRC","volume":"4","author":"Yeatman","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/08977190500199360","article-title":"c-Yes response to growth factor activation","volume":"23","author":"Clump","year":"2005","journal-title":"Growth Factors"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1634\/theoncologist.2009-0009","article-title":"The role of Src in solid tumors","volume":"14","author":"Wheeler","year":"2009","journal-title":"Oncologist"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1634\/theoncologist.2010-0408","article-title":"Current status of SRC inhibitors in solid tumor malignancies","volume":"16","author":"Puls","year":"2011","journal-title":"Oncologist"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.tips.2011.11.002","article-title":"Targeting Src family kinases in anti-cancer therapies: Turning promise into triumph","volume":"33","author":"Zhang","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.phrs.2015.08.010","article-title":"Fyn is an important molecule in cancer pathogenesis and drug resistance","volume":"100","author":"Elias","year":"2015","journal-title":"Pharmacol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/1947601910375273","article-title":"A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma","volume":"1","author":"Menges","year":"2010","journal-title":"Genes Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1158\/1535-7163.MCT-07-0052","article-title":"Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion","volume":"6","author":"Tsao","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/0008-5472.CAN-06-3633","article-title":"Identification ofcandidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection","volume":"67","author":"Huang","year":"2007","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jb\/mvr112","article-title":"Characterization of Kinase Inhibitors Using Different Phosphorylation States of Colony Stimulating factor-1 Receptor Tyrosine Kinase","volume":"151","author":"Kitagawa","year":"2012","journal-title":"J. Biochem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s40262-016-0391-6","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib","volume":"55","author":"Abbas","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/OTT.S189391","article-title":"Ponatinib: A novel multi-tyrosine kinase inhibitor against human malignancies","volume":"12","author":"Tan","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1021\/jm060434q","article-title":"N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src\/Abl kinase inhibitor","volume":"49","author":"Hennequin","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/bjc.2017.484","article-title":"A first-in-human phase i study to determine the maximum tolerated dose of the oral Src\/ABL inhibitor AZD0424","volume":"118","author":"Woodcock","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s10637-013-9929-8","article-title":"A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies","volume":"31","author":"Naing","year":"2013","journal-title":"Investig. New Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.2174\/1871520617666170103094946","article-title":"Inhibition of TGF-\u03b2 Signaling in Tumor Cells by Small Molecule Src Family Kinase Inhibitors","volume":"17","author":"Bartscht","year":"2017","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1074\/jbc.M209321200","article-title":"The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases","volume":"278","author":"Tatton","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20070797","article-title":"The selectivity of protein kinase inhibitors: A further update","volume":"408","author":"Bain","year":"2007","journal-title":"Biochem. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1517\/13543784.2010.499898","article-title":"Novel dual Src\/Abl inhibitors for hematologic and solid malignancies","volume":"19","author":"Schenone","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/nyas.13922","article-title":"Adenosine diphosphate regulates MMP2 and MMP9 activity in malignant mesothelioma cells","volume":"1431","author":"Muscella","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.bbrc.2014.04.037","article-title":"CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells","volume":"447","author":"Komiya","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3892\/etm.2011.270","article-title":"Bowman-Birk protease inhibitor from soybeans enhances cisplatin-induced cytotoxicity in human mesothelioma cells","volume":"2","author":"Kashiwagi","year":"2011","journal-title":"Exp. Ther. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1254\/jphs.08327FP","article-title":"Enhanced effect of connexin 43 on cisplatin-induced cytotoxicity in mesothelioma cells","volume":"110","author":"Sato","year":"2009","journal-title":"J. Pharmacol. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/onc.2011.286","article-title":"New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization","volume":"31","author":"Indovina","year":"2012","journal-title":"Oncogene"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/JTO.0b013e318248242c","article-title":"Cancer and Leukemia Group B Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): A brief report","volume":"7","author":"Dudek","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jtho.2017.10.033","article-title":"Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma","volume":"13","author":"Tsao","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.3892\/or.2015.4200","article-title":"Inhibition of Src family kinases overcomes anoikis resistance induced by spheroid formation and facilitates cisplatin-induced apoptosis in human mesothelioma cells","volume":"34","author":"Eguchi","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"76577","DOI":"10.18632\/oncotarget.10428","article-title":"Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines","volume":"7","author":"Monica","year":"2016","journal-title":"Oncotarget"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/260170a0","article-title":"DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA","volume":"260","author":"Stehelin","year":"1976","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.7150\/ijbs.5141","article-title":"Regulation of the Src family kinases by Csk","volume":"8","author":"Okada","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7957","DOI":"10.1038\/sj.onc.1208079","article-title":"The interplay between Src family kinases and receptor tyrosine kinases","volume":"23","author":"Bromann","year":"2004","journal-title":"Oncogene"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1164\/rccm.201807-1292OC","article-title":"YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib","volume":"200","author":"Garmendia","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_58","first-page":"320","article-title":"Upregulation of Tyrosine Kinase FYN in Human Thyroid Carcinoma: Role in Modulating Tumor Cell Proliferation, Invasion, and Migration","volume":"32","author":"Zheng","year":"2017","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1016\/j.celrep.2018.11.103","article-title":"Dual Mechanisms of LYN Kinase Dysregulation Drive Aggressive Behavior in Breast Cancer Cells","volume":"25","author":"Tornillo","year":"2018","journal-title":"Cell Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.addr.2010.11.001","article-title":"Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis","volume":"63","author":"Zhao","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/jcp.22335","article-title":"Phosphorylation of Ser 21 in Fyn regulates its kinase activity, focal adhesion targeting, and is required for cell migration","volume":"226","author":"Yeo","year":"2011","journal-title":"J. Cell. Physiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ijc.23579","article-title":"Lysophosphatidic acid induces ovarian cancer cell dispersal by activating Fyn kinase associated with p120-catenin","volume":"123","author":"Huang","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"10175","DOI":"10.18632\/oncotarget.3391","article-title":"Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells","volume":"6","author":"Chatterji","year":"2015","journal-title":"Oncotarget"},{"key":"ref_64","first-page":"a029207","article-title":"Adherens Junctions and Desmosomes Coordinate Mechanics and Signaling to Orchestrate Tissue Morphogenesis and Function: An Evolutionary Perspective","volume":"1010","author":"Broussard","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_65","first-page":"2430","article-title":"Src family kinase inhibitor PP2 restores the E-cadherin\/catenin cell adhesion system in human cancer cells and reduces cancer metastasis","volume":"8","author":"Nam","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1091\/mbc.e06-12-1154","article-title":"E-cadherin adhesion activates c-Src signaling at cell-cell contacts","volume":"18","author":"McLachlan","year":"2007","journal-title":"Mol. Biol. Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1016\/j.cub.2015.09.072","article-title":"Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion","volume":"25","author":"Vlahov","year":"2015","journal-title":"Curr. Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.2741\/4037","article-title":"Src-mediated regulation of E-cadherin and EMT in pancreatic cancer","volume":"17","author":"Nagathihalli","year":"2012","journal-title":"Front. Biosci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nrc1276","article-title":"Cell adhesion and signalling by cadherins and Ig-CAMs in cancer","volume":"4","author":"Cavallaro","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.devcel.2013.02.012","article-title":"Dynamic Regulation of the Structure and Functions of Integrin Adhesions","volume":"24","author":"Wolfenson","year":"2013","journal-title":"Dev. Cell"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"a023234","DOI":"10.1101\/cshperspect.a023234","article-title":"Actin-Based Adhesion Modules Mediate Cell Interactions with the Extracellular Matrix and Neighboring Cells","volume":"9","author":"Bachir","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1242\/jcs.039446","article-title":"Adhesion signaling\u2014Crosstalk between integrins, Src and Rho","volume":"122","author":"Huveneers","year":"2009","journal-title":"J. Cell Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccell.2019.01.007","article-title":"Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance","volume":"35","author":"Cooper","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1083\/jcb.200212114","article-title":"Differential regulation of cell motility and invasion by FAK","volume":"160","author":"Hsia","year":"2003","journal-title":"J. Cell Biol."},{"key":"ref_75","first-page":"1501","article-title":"Activation of the FAK-src molecular scaffolds and p130Cas-JNK signaling cascades by \u03b11-integrins during colon cancer cell invasion","volume":"31","author":"Grijelmo","year":"2007","journal-title":"Int. J. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"47931","DOI":"10.18632\/oncotarget.18201","article-title":"TRIB1 promotes colorectal cancer cell migration and invasion through activation MMP-2 via FAK\/Src and ERK pathways","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Olea-Flores, M., Zu\u00f1iga-Eulogio, M., Tacuba-Saavedra, A., Bueno-Salgado, M., S\u00e1nchez-Carvajal, A., Vargas-Santiago, Y., Mendoza-Catal\u00e1n, M.A., P\u00e9rez Salazar, E., Garc\u00eda-Hern\u00e1ndez, A., and Padilla-Benavides, T. (2019). Leptin Promotes Expression of EMT-Related Transcription Factors and Invasion in a Src and FAK-Dependent Pathway in MCF10A Mammary Epithelial Cells. Cells, 8.","DOI":"10.1101\/739169"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1038\/onc.2013.393","article-title":"Invading one step at a time: The role of invadopodia in tumor metastasis","volume":"33","author":"Paz","year":"2014","journal-title":"Oncogene"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"15059","DOI":"10.1038\/ncomms15059","article-title":"LPP is a Src substrate required for invadopodia formation and efficient breast cancer lung metastasis","volume":"8","author":"Ngan","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0837-z","article-title":"Aspartate \u03b2-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway","volume":"12","author":"Ogawa","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1038\/sj.onc.1205989","article-title":"Src activation regulates anoikis in human colon tumor cell lines","volume":"21","author":"Windham","year":"2002","journal-title":"Oncogene"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e2572","DOI":"10.1038\/cddis.2016.436","article-title":"RanBP9\/TSSC3 complex cooperates to suppress anoikis resistance and metastasis via inhibiting Src-mediated Akt signaling in osteosarcoma","volume":"7","author":"Dai","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2018.09.033","article-title":"ZNF32 induces anoikis resistance through maintaining redox homeostasis and activating Src\/FAK signaling in hepatocellular carcinoma","volume":"442","author":"Li","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0042-6822(91)90583-W","article-title":"Induction of a diffuse mesothelioma in chickens by intraperitoneal inoculation of v-src DNA","volume":"182","author":"England","year":"1991","journal-title":"Virology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s10495-006-9235-4","article-title":"Involvement of IL-10 and Bcl-2 in resistance against an asbestos-induced apoptosis of T cells","volume":"11","author":"Miura","year":"2006","journal-title":"Apoptosis"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/carcin\/bgs109","article-title":"Deficiency of Fyn Protein Is Prerequisite for Apoptosis Induced by Src Family Kinase Inhibitors in Human Mesothelioma Cells","volume":"33","author":"Eguchi","year":"2012","journal-title":"Carcinogenesis"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3892\/or.2012.2010","article-title":"Yes is a central mediator of cell growth in malignant mesothelioma cells","volume":"28","author":"Sato","year":"2012","journal-title":"Oncol. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng1343","article-title":"Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia","volume":"36","author":"Hu","year":"2004","journal-title":"Nat. Genet."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ccell.2016.09.007","article-title":"LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia","volume":"30","author":"Nguyen","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.1073\/pnas.1103904108","article-title":"Differential transformation capacity of Src family kinases during the initiation of prostate cancer","volume":"108","author":"Cai","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2017.03.006","article-title":"Inhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated Colon Cancer Progression","volume":"31","author":"Poh","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/15384047.2017.1416937","article-title":"Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma","volume":"19","author":"Kanteti","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"237ra68","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: A synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","article-title":"Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK","volume":"25","author":"Poulikakos","year":"2006","journal-title":"Oncogene"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1158\/1078-0432.CCR-07-0110","article-title":"Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors","volume":"13","author":"Inamoto","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3389\/fonc.2018.00225","article-title":"Periostin: A Matricellular Protein with Multiple Functions in Cancer Development and Progression","volume":"8","author":"Alonso","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ejcts.2009.08.027","article-title":"Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma","volume":"37","author":"Schramm","year":"2010","journal-title":"Eur. J. Cardio-Thorac. Surg."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1102>3.0.CO;2-Y","article-title":"Expression and activity of matrix metalloproteases in human malignant mesothelioma cell lines","volume":"91","author":"Liu","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s007950200002","article-title":"Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinase, collagens, and Ki67 antigen in pleural malignant mesothelioma: An immunohistochemical and electron microscopic study","volume":"35","author":"Hirano","year":"2002","journal-title":"Med. Electron Microsc."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/sj.bjc.6600920","article-title":"Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura","volume":"88","author":"Edwards","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.proghi.2011.12.002","article-title":"Nuclear localization of Matrix metalloproteinases","volume":"47","author":"Mannello","year":"2012","journal-title":"Prog. Histochem. Cytochem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1038\/s41388-018-0669-2","article-title":"ADAM10 mediates malignant pleural mesothelioma invasiveness","volume":"38","author":"Bellefroid","year":"2019","journal-title":"Oncogene"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/febs.15026","article-title":"SRC fine-tunes ADAM10 shedding activity to promote pituitary adenoma cell progression","volume":"287","author":"Huang","year":"2020","journal-title":"FEBS J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12195-018-00564-x","article-title":"Cell\u2013Cell Mechanical Communication in Cancer","volume":"12","author":"Schwager","year":"2019","journal-title":"Cell. Mol. Bioeng."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.canlet.2016.07.037","article-title":"Gap junction as an intercellular glue: Emerging roles in cancer EMT and metastasis","volume":"381","author":"Mao","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/carcin\/14.8.1597","article-title":"Gap junctional intercellular communication of primary and asbestos-associated malignant human mesothelial cells","volume":"14","author":"Linnainmaa","year":"1993","journal-title":"Carcinogenesis"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1093\/carcin\/15.11.2673","article-title":"Expression of cell adhesion molecules and connexins in gap junctional intercellular communication deficient human mesothelioma tumour cell lines and communication competent primary mesothelial cells","volume":"15","author":"Pelin","year":"1994","journal-title":"Carcinogenesis"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"12751","DOI":"10.1074\/jbc.270.21.12751","article-title":"pp60src-mediated phosphorylation of connexin 43, a gap junction protein","volume":"270","author":"Loo","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"8544","DOI":"10.1074\/jbc.M005847200","article-title":"Interaction of c-Src with gap junction protein connexin-43. Role in the regulation of cell-cell communication","volume":"276","author":"Giepmans","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"111545","DOI":"10.1016\/j.ejmech.2019.07.048","article-title":"Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines","volume":"181","author":"Fallacara","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Cammarata, F.P., Torrisi, F., Forte, G.I., Minafra, L., Bravat\u00e0, V., Pisciotta, P., Savoca, G., Calvaruso, M., Petringa, G., and Cirrone, G.A.P. (2019). Proton therapy and src family kinase inhibitor combined treatments on U87 human glioblastoma multiforme cell line. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194745"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.4161\/cc.11.5.19519","article-title":"Antitumor activity of new pyrazolo[3,4-d] pyrimidine SRC kinase inhibitors in Burkitt lymphoma cell lines and its enhancement by WEE1 inhibition","volume":"11","author":"Cozzi","year":"2012","journal-title":"Cell Cycle"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/jcb.25042","article-title":"SRC family kinase inhibition through a new pyrazolo[3,4-d]pyrimidine derivative as a feasible approach for glioblastoma treatment","volume":"116","author":"Ceccherini","year":"2015","journal-title":"J. Cell. Biochem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"12421","DOI":"10.18632\/oncotarget.3043","article-title":"SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation","volume":"6","author":"Casini","year":"2015","journal-title":"Oncotarget"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jcp.25397","article-title":"SRC Family Kinase Inhibition in Ewing Sarcoma Cells Induces p38 MAP Kinase-Mediated Cytotoxicity and Reduces Cell Migration","volume":"232","author":"Indovina","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1158\/1535-7163.MCT-15-1011","article-title":"Suppression of SRC signaling is effective in reducing synergy between glioblastoma and stromal cells","volume":"15","author":"Calgani","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3389\/fphar.2016.00416","article-title":"A pyrazolo[3,4-d]pyrimidine compound reduces cell viability and induces apoptosis in different hematological malignancies","volume":"7","author":"Laurenzana","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/biof.1382","article-title":"Differentially activated Src kinase in chemo-na\u00efve human primary osteosarcoma cells and effects of a Src kinase inhibitor","volume":"43","author":"Laschi","year":"2017","journal-title":"BioFactors"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Fallacara, A.L., Zamperini, C., Podolski-Reni\u0107, A., Dini\u0107, J., Stankovi\u0107, T., Stepanovi\u0107, M., Mancini, A., Rango, E., Iovenitti, G., and Molinari, A. (2019). A new strategy for glioblastoma treatment: In vitro and in vivo preclinical characterization of Si306, a pyrazolo[3,4-d]pyrimidine dual Src\/P-Glycoprotein inhibitor. Cancers, 11.","DOI":"10.3390\/cancers11060848"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1158\/1078-0432.CCR-06-2981","article-title":"Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects","volume":"13","author":"Johnson","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"31858","DOI":"10.1074\/jbc.C100271200","article-title":"Regulation of Akt\/PKB Activation by Tyrosine Phosphorylation","volume":"276","author":"Chen","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"15789","DOI":"10.1074\/jbc.M212525200","article-title":"Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation","volume":"278","author":"Jiang","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/sj.onc.1208744","article-title":"Human and mouse mesotheliomas exhibit elevated AKT\/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1038\/bjc.2014.220","article-title":"Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma","volume":"110","author":"Zhou","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1038\/s41388-018-0214-3","article-title":"RBL2\/p130 is a direct AKT target and is required to induce apoptosis upon AKT inhibition in lung cancer and mesothelioma cell lines","volume":"37","author":"Pentimalli","year":"2018","journal-title":"Oncogene"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"11","DOI":"10.18632\/oncoscience.467","article-title":"RBL2\/p130: A direct AKT substrate and mediator of AKT inhibition-induced apoptosis","volume":"5","author":"Ventura","year":"2018","journal-title":"Oncoscience"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2006.11.049","article-title":"p27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2","volume":"128","author":"Chu","year":"2007","journal-title":"Cell"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc2347","article-title":"The Cdk inhibitor p27 in human cancer: Prognostic potential and relevance to anticancer therapy","volume":"8","author":"Chu","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1038\/sj.onc.1209481","article-title":"Negative cell cycle regulator 14-3-3\u03c3 stabilizes p27 Kip1 by inhibiting the activity of PKB\/Akt","volume":"25","author":"Yang","year":"2006","journal-title":"Oncogene"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1128\/MCB.22.7.2025-2036.2002","article-title":"Control of Cell Cycle Exit and Entry by Protein Kinase B-Regulated Forkhead Transcription Factors","volume":"22","author":"Kops","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1038\/sj.onc.1203947","article-title":"Induction of p21(WAF1\/CIP1) and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: Role of activated STAT3 signaling","volume":"19","author":"Sinibaldi","year":"2000","journal-title":"Oncogene"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","article-title":"CDK inhibitors: Positive and negative regulators of G1-phase progression","volume":"13","author":"Sherr","year":"1999","journal-title":"Genes Dev."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1365-2559.2001.01136.x","article-title":"p27 immunostaining is related to prognosis in malignant mesothelioma","volume":"38","author":"Beer","year":"2001","journal-title":"Histopathology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/1097-0142(20010901)92:5<1245::AID-CNCR1444>3.0.CO;2-G","article-title":"p27(kip1) Immunoreactivity Correlates with Long-Term Survival in Pleural Malignant Mesothelioma","volume":"92","author":"Bongiovanni","year":"2001","journal-title":"Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/thx.2003.008912","article-title":"Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma","volume":"59","author":"Baldi","year":"2004","journal-title":"Thorax"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/cdd.2009.32","article-title":"Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates","volume":"16","author":"Daubriac","year":"2009","journal-title":"Cell Death Differ."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/1535-7163.MCT-13-0726","article-title":"Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with Src kinase inhibitors","volume":"13","author":"Liu","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Liu, R., Ferguson, B.D., Zhou, Y., Naga, K., Salgia, R., Gill, P.S., and Krasnoperov, V. (2013). EphB4 as a therapeutic target in mesothelioma. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-269"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.lfs.2009.02.007","article-title":"A redox-silent analogue of tocotrienol acts as a potential cytotoxic agent against human mesothelioma cells","volume":"84","author":"Kashiwagi","year":"2009","journal-title":"Life Sci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1328","article-title":"Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors","volume":"25","author":"Bantscheff","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nchembio.332","article-title":"A chemical and phosphoproteomic characterization of dasatinib action in lung cancer","volume":"6","author":"Li","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1128\/MCB.20.18.6779-6798.2000","article-title":"Both Src-Dependent and -Independent Mechanisms Mediate Phosphatidylinositol 3-Kinase Regulation of Colony-Stimulating Factor 1-Activated Mitogen-Activated Protein Kinases in Myeloid Progenitors","volume":"20","author":"Lee","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.leu.2404986","article-title":"Src-family kinases play an essential role in differentiation signaling downstream of macrophage colony-stimulating factor receptors mediating persistent phosphorylation of phospholipase C-\u03b32 and MAP kinases ERK1 and ERK2","volume":"22","author":"Grasset","year":"2008","journal-title":"Leukemia"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fonc.2020.00388","article-title":"The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models","volume":"10","author":"Blanquart","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jtho.2018.08.2036","article-title":"Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","volume":"13","author":"Tsao","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrc.2016.25","article-title":"Targeting metastasis","volume":"16","author":"Steeg","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/annonc\/mdn291","article-title":"Targeting Src in Breast Cancer","volume":"8","author":"Finn","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature04296","article-title":"Oncogenic pathway signatures in human cancers as a guide to targeted therapies","volume":"439","author":"Bild","year":"2006","journal-title":"Nature"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"R255","DOI":"10.1186\/gb-2007-8-11-r255","article-title":"Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: Rationale for patient selection and efficacy monitoring","volume":"8","author":"Reeves","year":"2007","journal-title":"Genome Biol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10549-006-9463-x","article-title":"Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type\/\u201dtriple-negative\u201d breast cancer cell lines growing in vitro","volume":"105","author":"Finn","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/sj.bjc.6605381","article-title":"Activity of the multikinase inhibitor dasatinib against ovarian cancer cells","volume":"101","author":"Konecny","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1158\/1078-0432.CCR-13-2141","article-title":"Cross-talk between EphA2 and BRaf\/CRaf is a key determinant of response to dasatinib","volume":"20","author":"Huang","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1074\/mcp.M111.016410","article-title":"Phosphosignature predicts dasatinib response in non-small cell lung cancer","volume":"11","author":"Klammer","year":"2012","journal-title":"Mol. Cell. Proteom."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2217\/fon-2017-0307","article-title":"A review of bevacizumab in the treatment of malignant pleural mesothelioma","volume":"13","author":"Brosseau","year":"2017","journal-title":"Future Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1083\/jcb.200408130","article-title":"Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis","volume":"167","author":"Weis","year":"2004","journal-title":"J. Cell Biol."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Huveldt, D., Lewis-Tuffin, L.J., Carlson, B.L., Schroeder, M.A., Rodriguez, F., Giannini, C., Galanis, E., Sarkaria, J.N., and Anastasiadis, P.Z. (2013). Targeting Src Family Kinases Inhibits Bevacizumab-Induced Glioma Cell Invasion. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056505"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1479-5876-12-148","article-title":"Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy","volume":"12","author":"Xu","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/ijc.26303","article-title":"Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration","volume":"130","author":"Bai","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.molimm.2004.04.010","article-title":"Src-family kinases: Rheostats of immune cell signaling","volume":"41","author":"Lowell","year":"2004","journal-title":"Mol. Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1007\/s00018-018-2863-3","article-title":"Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma","volume":"75","author":"Yu","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Dwyer, A.R., Greenland, E.L., and Pixley, F.J. (2017). Promotion of tumor invasion by tumor-associated macrophages: The role of CSF-1-activated phosphatidylinositol 3 kinase and Src family kinase motility signaling. Cancers, 9.","DOI":"10.3390\/cancers9060068"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1084\/jem.20171440","article-title":"Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity","volume":"215","author":"Hoves","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1111\/cas.12816","article-title":"Non-autonomous overgrowth by oncogenic niche cells: Cellular cooperation and competition in tumorigenesis","volume":"106","author":"Enomoto","year":"2015","journal-title":"Cancer Sci."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/7\/1866\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:50:10Z","timestamp":1760176210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/7\/1866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,11]]},"references-count":168,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["cancers12071866"],"URL":"https:\/\/doi.org\/10.3390\/cancers12071866","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,11]]}}}